Lactulose

Generic Name: Lactulose

Brand Names: Constulose, Enulose, Generlac, Kristalose

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₂O_₁₁

CAS Number: 4618-18-2

Unique Ingredient Identifier: 9XH2P2N8EP

Background: Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE). Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipa...

Indication: Lactulose is indicated for use as a laxative in the treatment of chronic constipation in adults and geriatric patients.
...

Associated Conditions: Constipation, Hepatic Encephalopathy (HE)

Associated Therapies: -

Clinical Trials

PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy

Phase 4

Conditions: Hepatic Encephalopathy

Interventions: Drug: Lactulose
Drug: Polyethylene Glycol

First Posted Date: 2017-04-04

Last Posted Date: 2017-04-27

Lead Sponsor: Sherief Abd-Elsalam

Target Recruit Count: 100

Registration Number: NCT03100513

Locations: 🇪🇬
Tropical medicine dept.-Tanta university hospital, Cairo, Egypt

Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy

Phase 2

Conditions: Encephalopathy, Hepatic

Interventions: Drug: Nitazoxanide
Drug: Lactulose

First Posted Date: 2015-06-08

Last Posted Date: 2017-08-21

Lead Sponsor: Sherief Abd-Elsalam

Target Recruit Count: 120

Registration Number: NCT02464124

Locations: 🇪🇬
Tanta university - faculty of medicine, Tanta, Elgharbia, Egypt

Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.

Not Applicable

Completed

Conditions: Acute-On-Chronic Liver Failure

Interventions: Drug: Lactulose + Rifaximin
Drug: Lactulose

First Posted Date: 2014-12-22

Last Posted Date: 2018-02-08

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 73

Registration Number: NCT02321371

Locations: 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India

Anal Dilatation for Infants and Children With Constipation

Not Applicable

Conditions: Constipation

Interventions: Drug: Lactulose

First Posted Date: 2014-10-03

Last Posted Date: 2014-10-03

Lead Sponsor: Tongji Hospital

Target Recruit Count: 100

Registration Number: NCT02255747

Locations: 🇨🇳
Tongji Hospital, Wuhan, Hubei, China

Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation

Phase 4

Completed

Conditions: Constipation

Interventions: Drug: Prucalopride
Drug: Polyethylene glycol (PEG)
Drug: Lactulose

First Posted Date: 2014-08-29

Last Posted Date: 2017-09-15

Lead Sponsor: Xian-Janssen Pharmaceutical Ltd.

Target Recruit Count: 280

Registration Number: NCT02228616

Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding

Phase 4

Completed

Conditions: Hepatic Encephalopathy

Interventions: Drug: Lactulose
Drug: L-ornithine L-aspartate
Drug: Rifaximin
Drug: Placebo

First Posted Date: 2014-06-06

Last Posted Date: 2018-05-22

Lead Sponsor: Hospital General de Mexico

Target Recruit Count: 88

Registration Number: NCT02158182

Locations: 🇲🇽
Hospital General de Mexico, Mexico City, Mexico

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

Phase 3

Withdrawn

Conditions: Hepatic Encephalopathy

Interventions: Drug: Rifaximin
Drug: Lactulose

First Posted Date: 2014-03-13

Last Posted Date: 2016-03-02

Lead Sponsor: NYU Langone Health

Registration Number: NCT02086825

Locations: 🇺🇸
New York University Langone Medical Center, New York, New York, United States

Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)

Not Applicable

Withdrawn

Conditions: Cirrhosis
AMS
Hepatic Encephalopathy
HE
Altered Mental Status

Interventions: Drug: Lactulose
Drug: Polyethylene Glycol 3350

First Posted Date: 2013-08-15

Last Posted Date: 2015-05-12

Lead Sponsor: New York Presbyterian Brooklyn Methodist Hospital

Registration Number: NCT01923376

Locations: 🇺🇸
New York Methodist Hospital, Brooklyn, New York, United States

Quality of Life and Nutritional Improvements in Cirrhotic Patients

Phase 4

Terminated

Conditions: Portal Hypertension
Liver Cirrhosis
Hepatic Encephalopathy

Interventions: Drug: Rifaximin
Drug: Lactulose
Drug: Rifaximin Placebo
Drug: Lactulose Placebo

First Posted Date: 2013-04-29

Last Posted Date: 2013-09-23

Lead Sponsor: Tampa General Hospital

Target Recruit Count: 4

Registration Number: NCT01842113

Locations: 🇺🇸
Tampa General Medical Group, Tampa, Florida, United States

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Phase 4

Completed

Conditions: Hepatic Encephalopathy
Cirrhosis

Interventions: Drug: Rifaximin
Drug: Lactulose

First Posted Date: 2013-04-29

Last Posted Date: 2019-09-09

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 222

Registration Number: NCT01842581

Locations: 🇺🇸
The Center for Liver and Biliary Disease, Baltimore, Maryland, United States
🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States

and more 33 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy